{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:11:50Z","timestamp":1758935510483,"version":"3.35.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.bbrc.2008.09.157","type":"journal-article","created":{"date-parts":[[2008,10,17]],"date-time":"2008-10-17T08:34:08Z","timestamp":1224232448000},"page":"453-457","source":"Crossref","is-referenced-by-count":25,"title":["Geranylgeranyl transferase type II inhibition prevents myeloma bone disease"],"prefix":"10.1016","volume":"377","author":[{"given":"Michelle A.","family":"Lawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les","family":"Coulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2008.09.157_bib1","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1074\/jbc.271.10.5289","article-title":"Protein prenyltransferases","volume":"271","author":"Casey","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2008.09.157_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2008.09.157_bib3","first-page":"5","article-title":"Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients\u2014the American experience","volume":"87","author":"Berenson","year":"1996","journal-title":"Br. J. Clin. Pract. Suppl."},{"key":"10.1016\/j.bbrc.2008.09.157_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib5","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.bbrc.2008.09.157_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"van Beek","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2008.09.157_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2008.09.157_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","article-title":"Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase","volume":"373","author":"Bergstrom","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2008.09.157_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"unstructured":"M.A. Lawson, Z. Xia, B.L. Barnett, J.T. Triffitt, R.J. Phipps, J.E. Dunford, R.M. Locklin, F.H. Ebetino, R.G.G. Russell, Differences between bisphosphonates in binding affinities for hydroxyapatite, J. Biomed. Mater. Res., submitted for publication.","key":"10.1016\/j.bbrc.2008.09.157_bib10"},{"key":"10.1016\/j.bbrc.2008.09.157_bib11","first-page":"5294","article-title":"The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway","volume":"58","author":"Shipman","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2008.09.157_bib12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ijc.21977","article-title":"Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells","volume":"119","author":"Roelofs","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.09.157_bib13","doi-asserted-by":"crossref","first-page":"48213","DOI":"10.1074\/jbc.M106473200","article-title":"Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages","volume":"276","author":"Coxon","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2008.09.157_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bone.2005.04.021","article-title":"Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo","volume":"37","author":"Coxon","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bbrc.2008.09.157_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S8756-3282(98)00120-3","article-title":"Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure\u2013activity relationships","volume":"23","author":"van Beek","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bbrc.2008.09.157_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib17","first-page":"593","article-title":"Animal model of human disease. Multiple myeloma","volume":"132","author":"Radl","year":"1988","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.09.157_bib19","first-page":"191","article-title":"The 5T2MM murine model of multiple myeloma: maintenance and analysis","volume":"113","author":"Vanderkerken","year":"2005","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bbrc.2008.09.157_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbrc.2008.09.157_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/ijc.22478","article-title":"Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo","volume":"120","author":"Edwards","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.09.157_bib22","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","article-title":"Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma","volume":"6","author":"Scavelli","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2008.09.157_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","article-title":"Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma","volume":"119","author":"Gordon","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib24","first-page":"217","article-title":"Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity","volume":"109\u2013110","author":"Ebetino","year":"1996","journal-title":"Phosphorus Sulfur Silicon"},{"key":"10.1016\/j.bbrc.2008.09.157_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2008.09.157_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0301-472X(01)00618-X","article-title":"Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma","volume":"29","author":"Cruz","year":"2001","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbrc.2008.09.157_bib28","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2008.09.157_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/0008-5472.CAN-06-1287","article-title":"An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma","volume":"67","author":"Heath","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2008.09.157_bib30","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X0801944X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X0801944X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:57:49Z","timestamp":1738450669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X0801944X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0006291X0801944X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2008.09.157","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}